Latest News

Poor adherence to migraine prophylaxis

 

Short-term adherence to migraine prophylaxis is poor, with about one-half of patients stopping their medication within a year, according to the results of a systematic review (Hepp et al. J Manag Care Pharm 2014;20:22-33). Read More

Combining drug and psychotherapy more effective for depression, anxiety

 

A new meta-analysis has concluded that combining psychotherapy with pharmacotherapy is more effective than either treatment alone in managing patients with major depression, panic disorder or obsessive-compulsive disorder (Cuijpers et al. World Psychiatry 2014;13:56-67; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC3918025/pdf/wps0013-0056.pdf). Read More

New data for daclizumab in MS

 

Daclizumab is an IgG1 anti-CD25 monoclonal antibody that blocks IL-2-mediated lymphocyte activation. The drug (Zenapax) was originally used to prevent tissue rejection but was withdrawn by Roche in 2009 due to declining demand.      Read More

TOPICS: